Aastha Dheer

Dr. Aastha Dheer

Department of Neurology, Mayo Clinic, Rochester, MN, USA
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2020 in Glia
Verified
Journal Article
Closed access
PDF file
YWYujia Wei
Yujia Wei
TCTingjun Chen
Tingjun Chen
DBDale B. Bosco
Dale B. Bosco
MXManling Xie
Manling Xie
JZJiaying Zheng
Jiaying Zheng
LWLong‐Jun Wu
Long‐Jun Wu

19 March 2021 in PLOS Biology
Verified
Journal Article
Open access
PDF file
MYMin-Hee Yi
Min-Hee Yi
YLYong U. Liu
Yong U. Liu
AUAnthony D. Umpierre
Anthony D. Umpierre
TCTingjun Chen
Tingjun Chen
YYYanlu Ying
Yanlu Ying
LWLong-Jun Wu
Long-Jun Wu
Spinal microglia are highly responsive to peripheral nerve injury and are known to be a key player in pain. However, there has not been direct evidence showing that selective microglial activation in vivo is sufficient to induce chronic pain. Here, we used optogenetic approaches in microglia to address this question employing CX3CR1creER/+: R26LSL-ReaChR/+ transgenic mice, in which red-activated channelrhodopsin (ReaChR) is inducibly and specifically expressed in microglia. We found that activation of ReaChR by red light in spinal microglia evoked reliable inward currents and membrane depolarization. In vivo optogenetic activation of microglial ReaChR in the spinal cord triggered chronic pain hypersensitivity in both male and female mice. In addition, activation of microglial ReaChR up-regulated neuronal c-Fos expression and enhanced C-fiber responses. Mechanistically, ReaChR activation led to a reactive microglial phenotype with increased interleukin (IL)-1β production, which is likely mediated by inflammasome activation and calcium elevation. IL-1 receptor antagonist (IL-1ra) was able to reverse the pain hypersensitivity and neuronal hyperactivity induced by microglial ReaChR activation. Therefore, our work demonstrates that optogenetic activation of spinal microglia is sufficient to trigger chronic pain phenotypes by increasing neuronal activity via IL-1 signaling.

1 July 2018 in Neuroscience
Verified
Journal Article
Closed access
ADAastha Dheer
Aastha Dheer
VJV. Jain
V. Jain
NKN. Kushwah
N. Kushwah
RKR. Kumar
R. Kumar
DPD. Prasad
D. Prasad
SSS Singh
S Singh

5 July 2018 in Annals of Neurosciences
Verified
Journal Article
Open access
PDF file
RKRahul Kumar
Rahul Kumar
VJVishal Jain
Vishal Jain
NKNeetu Kushwah
Neetu Kushwah
ADAastha Dheer
Aastha Dheer
KMKamla Prasad Mishra
Kamla Prasad Mishra
SSShashi Bala Singh
Shashi Bala Singh
Hypobaric hypoxia (HH) is a major stress factor that is associated with physiological, biochemical, molecular and genomic alterations. Brain is the organ that reacts sensitively to oxygen deprivation, which leads to oxidative stress and cognitive function impairment. Our previous studies have reported that downregulation of brain derived neurotrophic factor (BDNF) leads to neurodegeneration and memory impairment. The aim of the present study was to investigate the effect of HH exposure on DNA methylation and its regulation in BDNF expression, neurodegeneration and spatial memory impairment. For this purpose, Sprague Dawley rats were exposed to HH at a simulated altitude of 25,000 feet for 14 days. Real-time polymerase chain reaction was used for transcriptional expression of DNA Methyltransferases (DNMTs) including DNMT1, DNMT3a and ­DNMT3b, and immunoblotting was used for the translational expression of DNMT1, DNMT3a, DNMT3b, Methyl CpG binding protein 2 (MeCP2), pMeCP2 and BDNF in rat hippocampus. Additionally, neuronal morphology alteration and neurodegeneration in CA1 region of hippocampus were investigated though Cresyl violet (CV) staining and Fluoro-Jade C staining respectively. Results obtained suggested that HH exposure increased the expression of DNMT1 DNMT3b at the mRNA as well as protein level, whereas no significant change was observed in the level of DNMT3a. Furthermore, the level of pMeCP2 and BDNF were significantly decreased; however, the expression level of MeCP2 was significantly increased. The CV and Fluoro-Jade C-positive cells were significantly enhanced in the CA1 region of hippocampus in the HH exposed group as compared to unexposed rats. Thus, the present study concluded that HH decreases neuronal activation by the upregulation of DNA methylation and MeCP2 and decreased the expression of pMeCP2, which result in the downregulation of BDNF. The decreased BDNF expression is associated with neuronal loss and spatial memory impairment. This study highlights that DNMT inhibition could be an important therapeutic target for neurodegenerative diseases.

6 November 2023 in Neuro-Oncology
Verified
Journal Article
Closed access
JZJiaying Zheng
Jiaying Zheng
LWLingxiao Wang
Lingxiao Wang
SZShunyi Zhao
Shunyi Zhao
WZWenjing Zhang
Wenjing Zhang
YCYuzhou Chang
Yuzhou Chang
LWLong-Jun Wu
Long-Jun Wu
Background: Myeloid cells comprise up to 50% of the total tumor mass in glioblastoma (GBM) and have been implicated in promoting tumor progression and immunosuppression. Modulating the response of myeloid cells to the tumor has emerged as a promising new approach for cancer treatment. In this regard, we focus on the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which has recently emerged as a novel immune modulator in peripheral tumors. Methods: We studied the TREM2 expression profile in various patient tumor samples and conducted single-cell transcriptomic analysis in both GBM patients and the GL261 mouse glioma model. We utilized multiple mouse glioma models and employed state-of-the-art techniques such as invivo 2-photon imaging, spectrum flow cytometry, and in vitro co-culture assays to study TREM2 function in myeloid cell-mediated phagocytosis of tumor cells, antigen presentation, and response of CD4+ T cells within the tumor hemispheres. Results: Our research revealed significantly elevated levels of TREM2 expression in brain tumors compared to other types of tumors in patients. TREM2 was predominantly localized in tumor-associated myeloid cells and was highly expressed in nearly all microglia, as well as various subtypes of macrophages. Surprisingly, in preclinical glioma models, TREM2 deficiency did not confer a beneficial effect; instead, it accelerated glioma progression. Through detailed investigations, we determined that TREM2 deficiency impaired the ability of tumor-myeloid cells to phagocytose tumor cells and led to reduced expression of MHCII. This deficiency further significantly decreased the presence of CD4+ T cells within the tumor hemispheres. Conclusions: Our study unveiled a previously unrecognized protective role of tumor-myeloid TREM2. Specifically, we found that TREM2 enhances the phagocytosis of tumor cells and promotes an immune response by facilitating MHCII-associated CD4+ T-cell responses against gliomas.

3 November 2023 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
ADAastha Dheer
Aastha Dheer
DBDale B. Bosco
Dale B. Bosco
JZJiaying Zheng
Jiaying Zheng
LWLingxiao Wang
Lingxiao Wang
SZShunyi Zhao
Shunyi Zhao
LWLong-Jun Wu
Long-Jun Wu